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Abstract
Introduction Lynch syndrome is an autosomal dominant disorder, most frequent leading to colon cancer. Identification of
patients with Lynch syndrome and screening of their family members are available prevention approach that can significantly
decrease mortality. Unfortunately, routine screening still does not belong to standard of care in Hungary. In this study, we
performed a comprehensive screening in order to identify patients with mismatch repair (MMR) mutation between the years
of 2011 and 2014. Identified mutations were compared with those already published in the international databases.
Patients and Methods Patients who underwent treatment for colorectal cancer at the Surgical Institute of the University of
Debrecen were screened using the modified Amsterdam and Bethesda Criteria. Immunohistochemistry and microsatellite anal-
yses were performed in order to identify possible mutation carrier cases. Suspicious cases underwent DNA sequencing to detect
mutations in the mismatch repair genes (hMLH1, hMSH2).
Results All together 760 colorectal cancer patients were screened. A total of 28 patients were identified as possible MMR
mutation carrier and underwent further genetic evaluation. Pathogenic sequence variants of the MMR gene were found in 5
patients. Hypermethylation of the promoter region of the hMLH1 gene was identified in 2 patients. Two out of the 5 pathogenic
sequence variants of the MMR gene were first identified by our group while other 2 mutations were previously published as
possible founder mutations.
Conclusion Identification of families with Lynch syndrome, while challenging because of variable phenotypes at diagnosis, is
feasible with available molecular biological technologies and crucial to reduce mortality caused by this syndrome.
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Introduction
General Characteristic of Lynch Syndrome
Hereditary nonpolyposis colorectal carcinoma (Lynch syn-
drome), also known as Lynch syndrome, is a highly penetrant,
autosomal dominant disease involving a mutation in one of
the four DNA mismatch repair (MMR) genes (MLH1,MSH2,
MSH6, or PMS2) or EPCAM. It is the most common cause of
inherited colorectal cancer (CRC), accounting for approxi-
mately 3–6% of all cases [1, 2]. In addition to an increased
risk of colorectal cancer, patients with Lynch syndrome have
increased susceptibility to other malignancies including endo-
metrial cancer and to a lesser extent gastric, small bowel,
ovarian, upper urinary tract, biliary tract, skin, and central
nervous system cancers [3].
Depending on which MMR gene is affected, lifetime risk
of CRC ranges between 80 and 90%. However, there are large
differences between studies evaluating the lifetime risk [4, 5].
The most common extra colic Lynch-associated tumor is en-
dometrial cancer which is mostly endometrioid subtype with
20–60% risk depending on the MMR gene mutation. Other
extra-colonic Lynch-associated tumors like ovarian cancers
are serous or mucinous type, with range from 0.3–20% of
lifetime risk [6, 7]. Gastric cancers are more likely intestinal
type. Its estimated lifetime risk in Lynch syndrome is 5–10%
[8]. The lifetime risk of small bowel cancer is between 0.4 and
12% with the appearance in the duodenum or ileum [9].
Urinary tract tumors in Lynch syndrome are transitional cell
carcinomas with the localization in the ureter and renal pelvis
but not in the bladder. Lifetime risk of this cancer ranges from
0.5 to 25% [10].
Most Lynch syndrome-associated tumors are adenocarci-
nomas. In fact, while individuals with Lynch syndrome devel-
op adenomas at a similar rate to general population, malignant
transformation requires considerably less time [11–13]. Thus,
compared with sporadic cases, Lynch syndrome-associated
CRC develops at an early age (median age of 45).
Furthermore, they tend to present in the proximal colon
(70% are right-sided tumors), synchronous and metachronous
CRCs are more common [3]. Due to these characteristics of
this disease above, aggressive screening is critical to reduce
mortality. Both recognition of affected patients and screening
of their families as well as the detection of germline mutation
of theMMR gene is a fundamental step. While clinical criteria
for Lynch syndrome such as the Bethesda and modified
Amsterdam criteria exist, it can miss up to 28–68% of the
affected families [14, 15]. Suboptimal sensitivity leads to the
evolution of alternative screening approaches including mi-
crosatellite instability (MSI) and immunohistochemistry
(IHC) analysis for MMR proteins in CRC cases. Sensitivity
for this screening approach is ~ 100% with a specificity of
93% [16]. As of 2016, multiple expert guidelines recommend
universal screening of all CRC patients. Patient testing is not
only implicated to rule out a germline mutation inMMR gene,
but may also impact prognosis and guide treatment for their
disease. For example, MSI-high tumors have better stage-
adjusted survival rates compared with microsatellite stable
disease. Further, adjuvant therapy studies have demonstrated
that there is no benefit of 5-fluorouracil (5-FU)-based treat-
ment in patients with MMR gene mutation. In vitro studies
have demonstrated that while CRC cells with a mutation of
one of theMMR genes might not respond to 5-FU-based treat-
ment, they may respond better to irinotecan (CPT11)-based
therapies. Further prospective clinical trials are needed to eval-
uate the effect of different chemotherapeutic regimes [17–19].
Patients and Methods
Patient Selection
All patients who underwent surgical intervention for CRC
between the years of 2011 and 2014 at the Surgical Institute
of the University of Debrecen were screened for Lynch syn-
drome using a questionnaire filled out by the physician based
on anamnesis. This questionnaire included a family history
expanding 3 generations applying the Amsterdam and
Bethesda criteria. There are several studies that evaluated the
sensitivity of the Amsterdam II and revised Bethesda criteria
by performing microsatellite instability or immunohistochem-
istry analysis or both tests as a primary screening tool in pro-
spective unselected series of RC patients. These studies find
that sensitivity of the Amsterdam II criteria for identifying
individuals with HNPCC syndrome was 40% and the sensi-
tivity of the revised Bethesda criteria was about 90%. Using
the Amsterdam II and Bethesda criterial together could in-
crease sensibility. According to the studies, if only revised
Bethesda guidelines is used, 10% of the patient who carry
MMR mutation could be excluded from the further molecular
testing, more likely who diagnosed with CRC in the age be-
tween of 50 and 60. [3–5] In those cases where Lynch syn-
drome was suspected, a paraffin-embedded, formalin-fixed
tumor sample was subjected to immunohistochemical staining
to evaluate the presence or absence of the nuclear protein
expression of MMR proteins. A peripheral blood sample
was also obtained. DNA was then isolated from both tumor
and peripheral blood samples to evaluate for MSI. We applied
two mononucleotide markers (BAT25, BAT26), and 3 dinu-
cleotide markers (D2S123, D5S346, D17S25) suggested by
the NCI workshop [20]. In the absence of any of the MMR
nuclear protein expression or in the presence of high MSI
status, patient DNAwas sequenced to detect MMR gene mu-
tation. Furthermore, we evaluated the hypermethylation of
MLH1 gene promoter region. Large deletions in hMLH1,
hMSH2, hMSH6, and the 3′-end of EPCAM gene were also
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tested. The presence of BRAF V600E point mutation was also
assessed in suspicious cases.
The study was approved by the University of Debrecen’s
Institutional Review Board and the Research Ethics
Committee of the Medical Research Council. All patients
gave written informed consent before initiation of any study
procedures.
Immunohistochemistry
Routine 5-μm-thick, formalin-fixed, paraffin-embedded tis-
sue sections were dewaxed, rehydrated, and treated in the
microwave oven in 10 mM citrate buffer (pH 6.4) for
20 min in order to restore antigenicity. Unspecific protein
binding was blocked with 1% bovine serum albumin contain-
ing PBS for 30 min at 37 °C, then slides were incubated
overnight with the primary antibodies (mouse monoclonal
anti-MSH2, clone 25D12, Labvision Corp., Fremont, CA,
USA, at 1:100 dilutions and mouse monoclonal anti-MLH1,
clone G168-15, Becton–Dickinson Biosciences, USA, at
1:100 dilutions), respectively. Primary antibodies were detect-
ed by a biotin–streptavidine detection kit (LSAB, Dako,
Carpinteria, CA, USA) using VIP chromogene. The slides
were counterstained with methyl green. Negative controls
were stained with the omission of the primary antibodies [20].
DNA Isolation from Paraffin-Embedded Tissue
Samples and Peripheral Blood of Lynch Syndrome
Patients
Paraffin-embedded cancerous tissue samples of the patients
were first deparaffinized with xylol, then rehydrated with eth-
anol. DNA was extracted by the use of High Pure PCR
Template Purification Kit (Roche Diagnostics, Mannheim,
Germany) or QIAamp DNA FFPE Tissue Kit (Qiagen,
Hilden, Germany). In the case of peripheral blood samples,
the DNAwas extracted with the use of QIAamp DNA Blood
Midi or Mini kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions.
Microsatellite Analysis
The DNA of the cancerous tissues and the corresponding
blood DNAwere used for testing MSI. Two mononucleotide
markers (BAT25 and BAT26) and 3 dinucleotide markers
(D2S123, D5S346, and D17S250) were studied according to
the international reference panel recommendations by the
Lynch Syndrome Microsatellite Instability Test (Roche
Diagnostics GmbH, Mannheim, Germany) [13, 20]. The
MSI status was assessed according to the consensus of the
National Cancer Institute Workshop on Microsatellite
Instability for Colorectal Cancer Detection. High level insta-
bility (MSI-H) was diagnosed when at least 30% of the
examined markers presented new alleles in the tumor tissue,
while low level instability (MSI-L) was observed when less
than 30% of the markers carried instability [20].
Sequencing of hMSH2 and hMLH1 Genes
All exons of hMH2 and hMLH1 genes were PCR-amplified
and sequenced in both directions. Sequencing reactions were
performed using BigDye Cyclce Sequencing kit v.3.1
(Applied Biosystems, Foster City, CA, USA). The semi-
automated fluorescence analysis was performed by the use
of ABI-PRISM 3130 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA) [20].
Testing Large Genomic Deletions
Deletions of one or more exons in hMLH1, hMSH2, and
hMSH6 genes and deletions of exons 8–9 in EPCAM gene
were tested with multiple ligation-dependent probe amplifica-
tion (MLPA) method using SALSA MLPA P003-B1 and
P072-C1 kits (MRC-Holland). Following intra- and inter-
sample normalization, copy number alterations were assessed
according to the manufacturer’s recommendations.
MLH1 Promoter Methylation Assay
Sodium bisulfite conversion of the tumor DNA samples was
carried out with EpiTect Bisulfite Kit (Qiagen) according to
the manufacturer’s instructions. We performed fluorescence-
based real-time PCR assay (Methylight) to assess the methyl-
ation level of the MLH1 promoter [21]. Primer and TaqMan
probe sets designed for bisulfite-converted DNA were used:
one set specific for a fully methylated sequence in the MLH1
promoter and a reference set designed for a CpG-free region of
the COL2A1 gene to normalize for input DNA. The primer
and probe sequences were previously described [22, 23].
EpiTect bisulfite-converted methylated and unmethylated hu-
man control DNA (Qiagen) were used as positive and nega-
tive controls. Real-time PCRs were carried out on ABI-7900
Sequence Detection System. The reaction mixes contained
0.5 μM of each primer, 0.2-μM probe, 4.0 mM MgCl2, and
JumpStart Taq ReadyMix (Sigma) in a final volume of 25 μl.
The thermal profile was the following: 95 °C for 5 min and
45 cycles of 95 °C for 15 s and 60 °C for 1 min. The percent-
age of fully methylated DNAmolecules (PMR) at the targeted
locus was calculated by dividing the [methylated
MLH1]:[COL2A1] ratio of the sample by the [methylated
MLH1]:[COL2A1] ratio of the positive control and multiplied
by 100. A sample was assessed as hypermethylated if the
average result of three parallel reached a minimum of 4
PMR [24].
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Detection of BRAF V600E Mutation
BRAF codon 600 was examined in DNA samples extracted
from formalin-fixed paraffin-embedded tumor tissue sections.
Polymerase chain reactions were performed in LightCycler2.0
instrument (Roche) using LightCycler FastStart DNA Master
SYBR Green I reaction mix (Roche) containing 2.5 mM
MgCl2 and 0.5 μM primers as previously described [25].
The cycling conditions were as follows: 95 °C for 10 min
and 45 cycles of 95 °C for 5 s, 60 °C for 10 s; 72 °C for
10 s. Sequencing reactions were performed with the referred
primers using BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems). The reaction products were run on
ABI3130 Genetic Analyzer.
Results
Screening for patients with Lynch syndrome has been an es-
sential part of our clinical investigation since 1997. So far,
screening tests have identified a number of patients with this
disease also showing new sequence variants of theMMR gene
that we have published recently. [20, 26, 27] Unfortunately, in
spite of our efforts to screen and follow this patient population
with Lynch syndrome, this has not become a routine clinical
investigation nationwide in Hungary as yet.
Patients Identified Based on Questionnaires
A total of 760 patients with colon cancer were interviewed
using the Bethesda and modified Amsterdam Criteria II be-
tween 2011 and 2014. Out of them, only 60 patients with
colorectal cancer (7.9%) met the criteria to be suspicious for
Lynch syndrome. Seventeen patients (28.3%) from these 60
were positive and found suspicious by modified Amsterdam
criteria and 43 (71.7%) were identified by Bethesda criteria.
These cases are summarized in annual breakdown in Table 1.
Results of Immunohistochemistry and Testing
for Microsatellite Instability Analysis
The IHC and MSI testings were completed in 51 of the 60
identified cases. We were unable to isolate enough tumor tis-
sue from the surgical specimen in the 9 remaining patients due
to complete pathologic response, i.e., in 7 cases as a result of
pre-operative chemo-radiation. The amount of available tu-
mor sample was not sufficient for testing in the last 2 cases.
IHC detected the loss of nuclear protein expression of at least
one of the evaluated MMR gene products in 25 (49%) of the
evaluated 51 cases. Using the 5 microsatellite markers to de-
termine MSI, there were 12 (23.5%) tumors with MSI-H sta-
tus and another 5 (9.8%)withMSI-L status from the evaluated
51 cases. The other 34 (66.7%) cases were microsatellite sta-
ble (MSS) as presented on Table 2.
Coding exons of hMLH1 and hMSH2 genes were se-
quenced in cases of MSI-H and/or cases of the loss of nuclear
protein expression found by IHC. All together, we selected 28
patients from this time period for further DNA analysis to
perform hypermethylation testing based on the results of the
questionnaires, IHC and MSI testings. We found 3 cases
where MSI-H status was found in spite of the normal IHC
staining. In one of these 3 cases, hypermethylation of the
hMLH1 gene promoter region was identified. In other 11 pa-
tients, we found loss of at least one of the MMR proteins
staining by IHC, but with MSS status. None of the patients
in this group had a mutation in the examinedMMR genes. All
patients who showed identified sequence variants in theMMR
genes had bothMSI-H status and loss of staining of thatMMR
protein by IHC (Table 2). These results suggest that MSI test-
ing has a higher specificity compared with IHC. If we had
performed only MSI testing as pre-screening in this popula-
tion followed by DNA sequencing as indicated by MSI-H
status, we would have received the same results.
In the group selected for DNA sequencing, there were 3
patients from 2011 and 2 from 2012 who did not have periph-
eral blood samples available, thus sequencing was unable to
be performed. We found that 2 out of these 5 patients had
MSI-H status and 3 had MSI-L status. Of these 5 patients, 3
were lost for follow-up and 2 subjects died because of rapid
disease progression. Due to these 5 missing samples, we
changed our blood drawing schedule. Previously, we had iso-
lated peripheral blood mononuclear cells (PBMC) for DNA
sequencing only after IHC and MSI testings were completed
and the results suggested a possible mutation. Since 2013, we
have begun collecting blood samples in EDTA-anticoagulated
tubes immediately after operation if the patient was found
positive by Bethesda or modified Amsterdam II criteria, but
well before any IHC or MSI data were available. Since these
Table 1 The screened patient
population between 2011 and
2014 with the number of positive
cases based on modified
Amsterdam and Bethesda criteria
in annual breakdown
Year Questionnaires were filled Suspect patients Amsterdam II positive Bethesda positive
2011 222 19 6 13
2012 213 14 5 9
2013 206 12 2 10
2014 119 15 4 11
Summary 760 60 17 43
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changes have been set, we have not missed any further blood
samples for sequencing.
Identified Sequence Variants in the MMR Genes
During the evaluation period, we identified 5 pathogenic se-
quence variants of the MMR genes and 2 cases of promoter
hypermethylation of hMLH1 from the 28 evaluated cases. So,
only 0.66% of patients who answered for the questionnaires
had MMR mutations. A mutation of hMLH1 gene was found
in 2 cases, 2 other mutations were identified in the hMSH2
gene, and one mutation was found in EPCAM gene (Table 3).
Interestingly, concurrent existence of promoter hypermethyla-
tion of hMLH1 and an hMSH2 pathogenic sequence variant
was found in one patient (patient 6; Table 3).
No BRAF Mutation Was Found in this Study
Population
It is well known that 100% of the patients with Lynch syn-
drome have MSI. About 15% of sporadic CRC cases also
have some MSI, which can be explained by the hMLH1 gene
promoter hypermethylation. Interestingly, 50–68% of theMSI
sporadic CRC cases had the V600E mutation of the BRAF
gene, which was found to be responsible for the development
of the CpG island methylator phenotype. Somatic inactivation
of the hMLH1 gene creates a Lynch syndrome phenotype
without the presence of an inherited MMR gene mutation.
Hence, evaluation of mutations in the BRAF gene can be a
cost-effective method to separate the MSI sporadic cases from
the inherited Lynch syndrome cases [28, 29]. With the appli-
cation of this method, we can avoid some of the more expen-
sive MMR gene mutation evaluations. There were no BRAF
mutations identified in our study population.
Results of the Evaluation for Promoter
Hypermethylation of the hMLH1 Gene
Two of our patients had promoter hypermethylation of the
hMLH1 gene (Table 3). Interestingly, one of these patients
also had an hMSH2 mutation. In the latter case, IHC showed
loss of nuclear expression of hMSH2.
Mutations Identified in the hMLH1 Gene
A pathogenic sequence variant of hMLH1 genewas found in 2
patients (Table 3). In patient #1, a missense mutation in codon
48, exon 2 (c.143A > C) was identified. This mutation results
in an amino acid change: from glutamine to proline (p.G48P).
We have previously published this mutation as it was found in
our several screened families [26, 27]. It has also been report-
ed by others as a pathogenic sequence variant of the MMR
Table 2 The results of the IHC,
MSI, and DNA analyses in annual
breakdown
Year Number of
patients
IHC (±)
*1
Microsatellite status Mutation found (yes/no)
2011 6 – 4 MSI-H, 2 MSI-L Yes (2 mutation), *2
6 – 6 MSS No
4 + 4 MSS No DNA analysis performed
2012 4 – 2 MSI-H, 2 MSI-L No, *3
2 – 2 MSS No
1 + 1 MSI-H No
6 + 6 MSS No DNA analysis performed
2013 2 – 2 MSI-H Yes (2 mutation, 1 hypermethylation of
hMLH-1 gene)
1 + 1 MSI-H No
8 + 8 MSS No DNA analysis performed
2014 2 – 1 MSI-H, 1 MSI-L Yes (1 mutation, 1 hypermethylation of
hMLH-1 gene)
3 – 3 MSS No
1 + 1 MSI-H No
5 + 5 MSS No DNA analysis performed
Summary 51 25+,
26-
12 MSI-H, 5 MSI-L,
34 MSS
5 mutations found
*1(−) one or more of the evaluated MMR nuclear expression was missing, (+) all MMR nuclear expression was
present
*2DNA analysis was not performed in 3 patients because peripheral blood samples were not available
*3DNA analysis was not performed in 2 patients because peripheral blood samples were not available
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genes causing Lynch syndrome [30], and can be found in
multiple databases, such as ClinVar, dbSNP, and OMIM data-
bases (https://www.ncbi.nlm.nih.gov/clinvar/variation/89739,
https://www.ncbi.nlm.nih.gov/snp/587778914). Based on
these circumstances, we suspect that this is a European
founder mutation.
During the DNA sequencing of the second patient, an ins >
frameshift>STOP mutation of the exon 11 of hMLH1 gene
was identified. This is a one-nucleotide insertion which causes
a frameshift when an extra cytosine is inserted into the 901
position. During translation, a proline will be inserted instead
of glutamine at the 301 position, and behind 5 more amino
acids there will be a STOP codon. Altogether, 4 new amino
acids will be expressed and then the translation will be stopped
(P-X-X-X-STOP). This mutation cannot be found in any of
the databases and was not published yet by other groups. We
believe that it is a new pathogenic sequence variants of the
MMR genes, which is responsible for the development of
Lynch syndrome in this patient.
Mutations Identified in the hMSH2 Gene
MSI-H status and absence of nuclear expression of the
hMSH2 and hMSH6 proteins were found in the third patient’s
tumor in Table 3. DNA sequencing revealed a pathogenic
nonsense mutation in exon 13 at codon 680 in the hMSH2
gene. An arginine to STOP codon change was caused by this
mutation, which results in a cytosine-thymine change at 2038
position, thus leading to premature protein chain termination.
It is a well-known pathogenic sequence variants of the MMR
genes causing Lynch syndrome and has been reported several
times in the literature. It can also be found in dbSNP and
ClinVar databases (https://www.ncbi.nlm.nih.gov/snp/
63749932, https://www.ncbi.nlm.nih.gov/clinvar/variation/
36572/#summary-evidence. Patient #6 had a simultaneous
hMLH1 promoter hypermethylation and hMSH2 gene
mutation on exon 14 showing a deletion→ frameshift→
STOP mutation. This mutation involves multiple nucleotide
(c.2366_2367del, c.2370_2375del; p.A789Vfs6*), which
causes a frameshift. As a consequence, the frameshift starts
at the 789 position in the protein, where valine is expressed in
instead of alanine. Five more codons then follow and the sixth
is a STOP codon (V-X-X-X-X-STOP). Based on the ClinVar
database, this region is very variable and multiple mutations
have been published, most of which were associated with
Lynch syndrome (https://www.ncbi.nlm.nih.gov/clinvar?
term=609309[MIM]). To the best of our knowledge, this
mutation has not been published so far. We believe that this
is a new pathogenic sequence variant from an unstable region
in the hMSH2 gene associated with Lynch syndrome.
Large Deletion Identified in the EPCAM Gene
The deletion of exon 9 of the EPCAM gene, which is associ-
ated with the hypermethylation of the hMSH2, was found in
one patient. This patient tumor was MSI-H positive and IHC
showed loss of nuclear expression of both the hMSH2 and
hMSH6 proteins. The 8th and 9th exons of the EPCAM gene
were deleted and following exon 9, the most 3′ exon this
deletion continued another 3 kb after the EPCAM gene creat-
ing a read-through mutation. Thus, an EPCAM-MSH2 fusion
transcript was created. Several EPCAM gene deletions were
published and it is well known that this generates read-through
mutations [31].
Absence of Mutations in Cases Suspicious for Lynch
Syndrome
All of the 5 patients who had pathogenic sequence variants of
the MMR genes in this study also had MSI-H status and ab-
sence of nuclear expression of at least one of the MMR pro-
teins on IHC. However, there was actually a total of nine
patients who were MSI-H six of which lost some of their
MMR protein expression. One MSI-H patient without muta-
tion showed hMLH1 promoter hypermethylation. We did not
find any pathogenic sequence variants in the MMR genes or
hypermethylation of the promoter region of the hMLH1 gene
in the other 3 patients. In spite of the non-mutated status, there
Table 3 The locations of the mutations and the 2 hMLH1 promoter hypermethylation
Sex Age at
diagnosis
Amsterdam
II
Bethesda MSI hMLH1 promoter
hypermethylation
Type of gene
mutation
Type of the mutation Mutation
1 F 44 no yes H no MLH1 Probably Founder c.143A > C; p.Q48P
2 M 40 no yes H no MLH1 New mutation c.901insC; p.Q301Pfs5*
3 M 43 no yes H no MSH2 Probably Founder c.2038C > T; p.R680X
4 M 32 yes no H no EPCAM Mutation del.ex.8–9-3-kb
downstream EPCAM
5 M 43 no yes H yes No mutation hMLH1
hypermethylation
–
6 F 30 yes no H yes MSH2 New mutation with hMLH1
hypermethylation
c.2366_2367del, c.2370_
2375del; p.A789Vfs6*
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are therapeutic and prognostic relevance of the MSI-H status
as we published previously [17–19]. The MSI-H status of
these patients is needed to put it into consideration when de-
cision made for the type of adjuvant chemotherapy and
follow-up schedule.
Discussion
In summary, out of the 760 patients with CRC that we former-
ly screened for Lynch syndrome between the years of 2011
and 2014, 5 pathogenic sequence variants of the MMR genes
and 2 cases of promoter hypermethylation of the hMLH1 gene
were identified. Interestingly, a mutation of hMSH2 and
hypermethylation of the hMLH1 promoter region were pres-
ent simultaneously in one patient. Two of these 5 sequence
variants of theMMR genes were identified for the first time by
our group. Two sequence variants of the MMR genes were
previously published, frequently seen, and possibly act as
founder mutations. Identification of these pathogenic se-
quence variants of the MMR genes, whether new or well
known, has important implications in our patient population
to decrease the mortality caused by Lynch syndrome.
Since clinical criteria, such as the Bethesda guidelines and
modified Amsterdam criteria, have low sensitivity and may
reduce the number of carriers, alternative strategies were ex-
plored to identify patients and their families with Lynch syn-
drome. Both IHC and MSI testings demonstrate similar sen-
sitivity as a screening test for this disease in patients with CRC
[14, 32]. In fact, during the pre-screening, we found that MSI
evaluation was more specific than IHC. If we did only MSI
testing, we would have received the same outcome in the
screening process. Other advantages of MSI analysis over
IHC include the possibility of identifying a tumor that has
defective MMR but retained staining on IHC (i.e., due to
non-truncating missense mutation) or one that has defective
MMR as a result of mutations in other genes besides hMLH1,
hMSH2, or hMSH6 and thus would be missed by IHC [33]. If
we identify a particular mutation to appear multiple times in
this region, it might be advised to directly analyze patients for
this mutation.
Furthermore, it is important to separate the MSI-H patients
without mutations as MSI-H status is associated with thera-
peutic and prognostic consequences [17–19]. For example,
MSI-H tumors have better stage-adjusted survival rates com-
pared with MSS disease and appears to be more prevalent in
stage II disease (~ 20%) [34]. Adjuvant therapy studies with 5-
FU have reported to show little to no benefit in MSI-H tumors
[35]. Retrospective analyses and in vitro studies, on the other
hand, have demonstrated potential benefits of other agents.
Retrospective analyses suggest some potential advantage of
adding oxaliplatin to 5-FU-based regimens [33] and in vitro
studies suggest that these MSI-H CRC cells may respond
better to irinotecan (CPT11)-based therapies [17–19].
Further prospective clinical trials are needed to evaluate the
effect of different chemotherapeutic regimes. Regardless, ei-
ther MSI-H status or MMR deficiency is a prognostic bio-
marker associated with lower risk of recurrence as well as a
predictive biomarker for lack of benefit from adjuvant 5-FU-
based chemotherapy [36].
Limitations of this study include that we could not perform
sequencing of the MMR and EPCAM genes for all patients to
confirm that there were no mutations in patients with MSS
status. In particular, tumors with germline hMSH6 mutations
may not show MSI-H status due to partial redundancy of
MSH6 and MSH3 proteins, which can limit MSI to mononu-
cleotide tandem repeats. Addition of other mononucleotide
markers, such as BAT-40, has re-classified some tumors with
MSI-L and MSS status to MSI-H and MSI-L, respectively
[33].
Conclusion
Mutation of genes in the DNA mismatch repair pathway is
implicated as the cause of Lynch syndrome. Our goal by prov-
ing the presence of germline mutation in one of the different
MMR gene in Lynch syndrome patients was to provide a basis
for accurate identification of the disease. Identification of fam-
ilies with Lynch syndrome, while challenging because of var-
iable phenotypes at diagnosis, is feasible with available mo-
lecular biological technologies and crucial to reduce mortality
caused by this syndrome. It is well known that the mortality of
Lynch syndrome can be effectively decreased in proven mu-
tation carriers and their families by performing colonoscopy
every 2 years, and annual gynecologic follow-up [3, 5, 17]. In
spite of this fact, the screening and identification of suspicious
mutation carriers are still not performed routinely in Hungary.
We have established a screening test in Eastern Hungary
some years ago and were able to identify and follow multiple
patients with Lynch syndrome. All together, 760 colorectal
cancer patients were screened. A total of 28 patients were
identified as possible MMR mutation carrier and underwent
further genetic evaluation. Pathogenic sequence variants of
the MMR genes were found in 5 patients. Hypermethylation
of the promoter region of the hMLH1 gene was identified in 2
patients. Two out of the 5 pathogenic sequence variants of the
MMR genes were first identified by our group while other 2
sequence variants of the MMR genes were previously pub-
lished as possible founder mutations. By finding 2 new muta-
tion during comprehensive screening in order to identify pa-
tients with mismatch repair mutation, we widen the interna-
tional data of the mutation types. In discovering new pathogen
mutations and showing practice of the screening in our clinic,
we would like to improve the efficacy of the identification of
patients with Lynch syndrome.
J Gastrointest Canc
We believe that the continuous screening of this patient
population with colorectal, ovarian, and endometrial cancer
and the close preventative oncologic follow-up of the new
identified cases and their family members will be applied na-
tionwide in all eastern European countries in the near future.
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